Volv Global joins Innovaud, One Nucleus & ARC West London to explore innovation and investment opportunities across the Lausanne London life sciences corridor.
Volv Global at ERS Congress 2026, presenting new research in collaboration with CSL Behring: Can We Catch ARDS Before It Strikes?
AI Innovation in Real-World Evidence & Data Analytics Volv Global has been selected as a finalist in the 2026 Fierce AI Innovation Awards, in the...
Volv Global applied machine learning to 24M UK primary care records, surfacing ~1,200 undiagnosed GEP-NET patients, 5–7 years younger than currently diagnosed
GEP-NETs are among the most diagnostically elusive tumours in oncology. This case study shows how machine learning applied to 24 million UK primary care records can identify ~1,200 likely-undiagnosed GEP-NET patients.
ASCO 2026 produced landmark oncology data. The question no one asked from the podium: can clinical infrastructure get patients across the gap to these drugs?
